A Cross-sectional, Mono-centric Pilot Study of Insulin Resistance in Enzyme Replacement Therapy Patients with Gaucher Type I Without Overweight
Overview
Authors
Affiliations
Insulin resistance have been demonstrated in untreated patients with Gaucher type I disease. It was implied in overweight enzyme replacement therapy (ERT) treated patients with Gaucher type I disease. In present study we investigate whether insulin resistance is presented in fourteen ERT treated patients with Gaucher type I disease and without overweight in comparison to normal subjects. This work illustrates the presence of insulin resistance in non-overweight ERT treated patients with Gaucher type I disease.
Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review.
Kaluzna M, Trzeciak I, Ziemnicka K, Machaczka M, Ruchala M Orphanet J Rare Dis. 2019; 14(1):275.
PMID: 31791361 PMC: 6889605. DOI: 10.1186/s13023-019-1211-5.
Ilan Y Front Immunol. 2019; 10:1143.
PMID: 31178868 PMC: 6538797. DOI: 10.3389/fimmu.2019.01143.
Doneda D, Netto C, Moulin C, Schwartz I Nutr Metab (Lond). 2013; 10(1):34.
PMID: 23570288 PMC: 3630065. DOI: 10.1186/1743-7075-10-34.
Sphingolipids: the nexus between Gaucher disease and insulin resistance.
Fuller M Lipids Health Dis. 2010; 9:113.
PMID: 20937139 PMC: 2964722. DOI: 10.1186/1476-511X-9-113.